Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation

Journal of Immunotherapy

Volumn 33, Issue 1, 2010, Pages 60-72

  Paine, Ananta ^a   Oelke, Mathias ^a   Tischer, Sabine ^a   Heuft, Hans Gert ^a   Blasczyk, Rainer ^a,b   Eiz Vesper, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; Antiviral T cells; CMVpp65; Human cytomegalovirus; Stem cell transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA A ANTIGEN; HYBRID PROTEIN; IMMEDIATE EARLY PROTEIN; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN HEK293; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INTERFERON PRODUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS IMMUNITY; VIRUS REACTIVATION;

ADOPTIVE TRANSFER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HLA ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; PHOSPHOPROTEINS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS;

EID: 74349110271     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b56dcc     Document Type: Article

References (43)

1. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008;40:71-75.
2. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol. 2004;65: 432-436.
3. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93: 248-256.
4. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seroposi-tive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240-2245.
5. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
6. Hobeika A, Osada T, Serra D, et al. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy. 2008; 10:289-302.
7. Liu Z, Savoldo B, Huls H, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002;159:123-133.
8. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76.
9. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97: 1232-1240.
10. Rentenaar RJ, Gamadia LE, van DerHoek N, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest. 2000;105:541-548.
11. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest. 1997;99:1739-1750.
12. Carlsson B, Cheng WS, Totterman TH, et al. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol. 2003;121:428-438.
13. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol. 2005;35:1795-1804.
14. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003;9: 619-624.
15. Paine A, Oelke M, Blasczyk R, et al. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion. 2007;47:2143-2152.
16. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomega-lovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood. 2001;97:994-1000.
17. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood. 1999;94:3242-3250.
18. Alp NJ, Allport TD, Van Zanten J, et al. Fine specificity of cellular immune responses in humans to human cytomegalo-virus immediate-early 1 protein. J Virol. 1991;65:4812-4820.
19. Borysiewicz LK, Graham S, Hickling JK, et al. Human cytomegalovirus- specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol. 1988;18: 269-275.
20. +-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77:5226-5240.
21. + T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol. 2004;172:2256-2264.
22. Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 2000;74:8140-8150.
23. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis. 2002;185:1709-1716.
24. + virus-specific cytotoxic T lymphocytes. J Med Virol. 1994;43:103-110.
25. Wills MR, Okecha G, Weekes MP, et al. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol. 2002;168:5455-5464.
26. + T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673-685.
27. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70:7569-7579.
28. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572.
29. Solache A, Morgan CL, Dodi AI, et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 1999;163:5512-5518.
30. Yao ZQ, Gallez-Hawkins G, Lomeli NA, et al. Site-directed mutation in a conserved kinase domain of human cytomega-lovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine. 2001;19:1628-1635.
31. Borst EM, Hahn G, Koszinowski UH, et al. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol. 1999; 73:8320-8329.
32. Seltsam A, Agaylan A, Grueger D, et al. Rapid detection of JMH antibodies with recombinant Sema7A (CD108) protein and the particle gel immunoassay. Transfusion. 2008;48: 1151-1155.
33. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lympho-cyte responses by interferon-gamma-enzyme-linked immuno-spot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 2002;99:3830-3837.
34. Mahajan SD, Aalinkeel R, Schwartz SA, et al. Effector cell mediated cytotoxicity measured by intracellular Granzyme B release in HIV infected subjects. Biol Proced Online. 2003; 5:182-188.
35. Eiz-Vesper B, Horn PA, Daubert C, et al. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells. Transfusion. 2006;46:1210-1220.
36. Liu YN, Kari B, Gehrz RC. Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol. 1988;62:1066-1070.
37. Schuler MM, Nastke MD, Stevanovikc S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol. 2007;409:75-93.
38. Somvanshi P, Singh V, Seth PK. Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development. Omics. 2008;12:61-69.
39. Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol. 2007;37:2441-2449.
40. Pelte C, Cherepnev G, Wang Y, et al. Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol. 2004;172:6783-6789.
41. Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008;82:546-554.
42. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98:754-761.
43. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998; 4:953-956.